New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
16:53 EDTQUREuniQure acquires InoCard in cash, stock
uniQure announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard founders Patrick Most and Hugo Katus will join uniQure as managing director of uniQure in Germany and chairman of the scientific advisory board, for cardiovascular diseases, respectively. Under the terms of the agreement, InoCard shareholders will receive an upfront payment of 3M, 1.5M in cash and 1.5M in uniQure stock, and certain success-based milestones and royalties.
News For QURE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
16:10 EDTQUREPoint72 Asset reports 5.0% passive stake in uniQure
Subscribe for More Information
08:50 EDTQUREuniQure price target lowered to $44 from $50 at Leerink
Leerink lowered its price target to $44 from $50 on uniQure after the company's Q2 report and pipeline update, noting that management said it is reassessing its development options for Glybera in the U.S. after the FDA said another trial would be required to support BLA filing. The firm said the company's key pipeline programs are on track, with initial data from hemophilia B and Sanfilippo B phase 1 trials expected in the second half, and keeps its Outperform rating on uniQure shares.
08:21 EDTQUREuniQure likely to delay Glybera U.S. registration indefinitely, says WallachBeth
Subscribe for More Information
07:25 EDTQUREuniQure weakness creates buying opportunity, says H.C. Wainwright
After uniQure reported a lower than expected per share loss, H.C. Wainwright believes that Hemphilia B is a key value driver for the stock. The firm notes that in a previous Phase 1 trial the same gene cassette being used by the company in an upcoming trial demonstrated continuous expression greater than 5% at the high dose and improved median bleeding episodes by 90%. The firm thinks that the stock should rise sharply if the current trial yields similar results. It keeps a $39 price target and Buy rating on the shares.
August 27, 2015
05:36 EDTQUREuniQure reports Q2 EPS (EUR 87c) vs. (EUR 51c) last year
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use